C Jacobi1, C Cursiefen. 1. Sicca-Spezialsprechstunde, Augenklinik mit Poliklinik, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen.
Abstract
BACKGROUND: Ocular complications are typical sequels of primary and secondary Sjögren's syndrome. Since these can lead to blindness in the case of insufficient therapeutic steps, diagnostic tools and therapeutic options in Sjögren-syndrome associated ocular diseases are outlined. METHODS: Literature review from PubMed and own clinical and experimental results. RESULTS: Numerous ocular complications can occur both in primary and secondary Sjögren's syndrome. The main problems involve tear film disturbances leading to severe forms of dry eye. CONCLUSION: Early and close cooperation between rheumatologist and ophthalmologist can avoid long-term complications in patients with Sjögren's disease and ocular complications.
BACKGROUND:Ocular complications are typical sequels of primary and secondary Sjögren's syndrome. Since these can lead to blindness in the case of insufficient therapeutic steps, diagnostic tools and therapeutic options in Sjögren-syndrome associated ocular diseases are outlined. METHODS: Literature review from PubMed and own clinical and experimental results. RESULTS: Numerous ocular complications can occur both in primary and secondary Sjögren's syndrome. The main problems involve tear film disturbances leading to severe forms of dry eye. CONCLUSION: Early and close cooperation between rheumatologist and ophthalmologist can avoid long-term complications in patients with Sjögren's disease and ocular complications.
Authors: D A Sullivan; H Yamagami; M Liu; R J Steagall; F Schirra; T Suzuki; K L Krenzer; J M Cermak; R M Sullivan; S M Richards; D A Schaumberg; M R Dana; B D Sullivan Journal: Adv Exp Med Biol Date: 2002 Impact factor: 2.622
Authors: Frank Schirra; Tomo Suzuki; Stephen M Richards; Roderick V Jensen; Meng Liu; Michael J Lombardi; Patricia Rowley; Nathaniel S Treister; David A Sullivan Journal: Invest Ophthalmol Vis Sci Date: 2005-10 Impact factor: 4.799
Authors: F Brignole; P J Pisella; M De Saint Jean; M Goldschild; A Goguel; C Baudouin Journal: Invest Ophthalmol Vis Sci Date: 2001-01 Impact factor: 4.799
Authors: Peter Szodoray; Philip Alex; Malin V Jonsson; Nicholas Knowlton; Igor Dozmorov; Britt Nakken; Nicolas Delaleu; Roland Jonsson; Michael Centola Journal: Clin Immunol Date: 2005-08-26 Impact factor: 3.969
Authors: Carol A Hitchon; Philip Alex; Lawrence B Erdile; Mark B Frank; Igor Dozmorov; Yuhong Tang; Keng Wong; Michael Centola; Hani S El-Gabalawy Journal: J Rheumatol Date: 2004-12 Impact factor: 4.666